Wed, June 17, 2020
Tue, June 16, 2020
Mon, June 15, 2020

David Amsellem Upgraded (SUPN) to Buy and Increased Target to $31 on, Jun 16th, 2020

David Amsellem of Piper Sandler, Upgraded "Supernus Pharmaceuticals, Inc." (SUPN) to Buy and Increased Target from $25 to $31 on, Jun 16th, 2020.

David has made no other calls on SUPN in the last 4 months.



There are 2 other peers that have a rating on SUPN. Out of the 2 peers that are also analyzing SUPN, all agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • David Steinberg of "Jefferies" Initiated at Hold and Held Target at $24 on, Monday, June 15th, 2020
  • Annabel Samimy of "Stifel" Maintained at Hold with Decreased Target to $24 on, Thursday, April 16th, 2020